

Levetiracetam

Catalog No: tcsc1854



Available Sizes

Size: 50mg

Size: 100mg

Size: 500mg

Size: 100g



Specifications

CAS No:

102767-28-2

Formula:

$C_8H_{14}N_2O_2$

Pathway:

Membrane Transporter/Ion Channel

Target:

Calcium Channel

Purity / Grade:

>98%

Solubility:

H₂O : ≥ 85 mg/mL (499.38 mM); DMSO : ≥ 85 mg/mL (499.38 mM)

Alternative Names:

UCB L059

Observed Molecular Weight:

170.21

Product Description

Levetiracetam(UCB L059) is a novel anticonvulsant with antihyperalgesic efficacy in inflammatory pain.

Target: Calcium Channel


Levetiracetam is used to control some types of seizures in patients with epilepsy. This medicine cannot cure epilepsy and will only work to control seizures for as long as you continue to use it. The exact mechanism for levetiracetam is unknown. However, the drug binds to a synaptic vesicle protein, SV2A, which is believed to impede nerve conduction across synapses [1].

Levetiracetam (10-200 mg/kg), ibuprofen (12.5-100 mg/kg), celecoxib (3.75-30 mg/kg), paracetamol (50-200 mg/kg), caffeine (15-100 mg/kg), and 2-drug combinations of levetiracetam with analgesics/caffeine produced a significant, dose-dependent reduction of inflammatory hyperalgesia. Isobolographic analysis revealed that levetiracetam exerts a synergistic interaction with analgesics, with approximately 7-, 9-, and 11-fold reduction of doses of both drugs in combination of levetiracetam with paracetamol, celecoxib, and ibuprofen, respectively. Analysis of the log dose-response curves for levetiracetam (1-50 mg/kg) in the presence of caffeine (10 mg/kg) and levetiracetam applied alone also revealed a synergistic interaction. Levetiracetam's ED₅₀ in the presence of caffeine was reduced approximately 11-fold [2].

Clinical indications: Epilepsy; Social phobia

FDA Approved Date: November 2008

Toxicity: depression; hallucinations; suicidal thoughts



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!